Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04503603 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04503603 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 12 participants.
The verdict
NCT04503603, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this study to evaluate the safety, tolerability and pharmacokinetics (PK) of lanadelumab administered by Intravenous (IV) infusion in healthy adult volunteers.
Interventions
- OTHER Placebo
- DRUG Lanadelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-08-10 |
| Est. Completion | 2020-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04503603
The ClinicalTrials.gov registry entry for NCT04503603 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04503603 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04503603 about?
NCT04503603 is a clinical study titled "A Study to Determine the Safety, Tolerability, and Pharmacokinetics of Lanadelumab Administered Intravenously in Healthy Adult Volunteer Participants". The purpose of this study to evaluate the safety, tolerability and pharmacokinetics (PK) of lanadelumab administered by Intravenous (IV) infusion in healthy adult volunteers.
What is the current status of trial NCT04503603?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2020-08-10. Estimated completion is 2020-12-23.
What interventions are being tested in trial NCT04503603?
The interventions under investigation include: Placebo (OTHER), Lanadelumab (DRUG).
Who is sponsoring clinical trial NCT04503603?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.